News & Videos - RELIEF THERAPEUTICS N

Relief Therapeutics Holding SA / Key word(s): Miscellaneous Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares 03.05.2023 / 07:00 CET/CEST Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares GENEVA (May 3, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF , OTCQB: RLFTF , RLFTY ) (Relief Therapeutics), a biopharmaceutical company committed to delivering innovative treatment options with the potential for...

GENEVA, SWITZERLAND / ACCESSWIRE / May 3, 2023 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief Therapeutics), a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to benefit those suffering from select specialty and rare diseases, today announced the implementation timeline for the reverse split of its ordinary shares, which was approved by shareholders at the Extraordinary General...

Relief Therapeutics Holding SA / Key word(s): Market Launch Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch Progressing Ahead of Schedule 01-May-2023 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch Progressing Ahead of Schedule Acer reports OLPRUVA™ drug availability...

Acer reports OLPRUVA™ drug availability anticipated in mid-June 2023; Acer is engaged in discussions with payers representing a substantial majority of covered lives; 70 percent of metabolic treatment providers surveyed by Acer at SIMD Annual Meeting indicated an interest in treating at least one of their patients with OLPRUVA™ in 2023 GENEVA, SWITZERLAND / ACCESSWIRE / May 1, 2023 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief Therapeutics), a...

Relief Therapeutics Holding SA / Key word(s): AGMEGM Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders 28.04.2023 / 19:00 CET/CEST Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders Shareholders approved all proposals by a large majority; Company to effectuate consolidation of ordinary shares in advance of planned Nasdaq Stock Market dual listing; ADR program will be terminated upon Nasdaq listing GENEVA (April 28, 2023)...

Shareholders approved all proposals by a large majority; Company to effectuate consolidation of ordinary shares in advance of planned Nasdaq Stock Market dual listing; ADR program will be terminated upon Nasdaq listing GENEVA, SWITZERLAND / ACCESSWIRE / April 28, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF, RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes...

Relief Therapeutics Holding SA / Key word(s): Research Update Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100 17-Apr-2023 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100 ® (Aviptadil Acetate) Relief to file a revised...

Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100 ® (Aviptadil Acetate) Relief to file a revised provisional patent application for RLF-100 ® based on the new stability results GENEVA, SWITZERLAND / ACCESSWIRE / April 17, 2023 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief Therapeutics, or Relief), a biopharmaceutical company committed to delivering innovative treatment options with the...

Relief Therapeutics Holding SA / Key word(s): Annual Results Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update 14-Apr-2023 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update GENEVA, April 14, 2023 – RELIEF THERAPEUTICS Holding SA (SIX: RLF , OTCQB: RLFTF , RLFTY )...

GENEVA, SWITZERLAND / ACCESSWIRE / April 3, 2023 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief Therapeutics, or Relief), a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to benefit those suffering from select specialty and rare diseases and disorders, today reported its financial results for the full-year ended December 31, 2022 and provided a corporate update. The Relief...

Relief Therapeutics Holding SA / Key word(s): Personnel Relief Therapeutics Announces Executive Leadership Team Change 05-Apr-2023 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therapeutics Announces Executive Leadership Team Change GENEVA, APRIL 5, 2023 – RELIEF THERAPEUTICS Holding SA (SIX: RLF , OTCQB: RLFTF , RLFTY ) ("Relief Therapeutics" or the "Company"), a biopharmaceutical company...

GENEVA, SWITZERLAND / ACCESSWIRE / April 5, 2023 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) ("Relief Therapeutics" or the "Company"), a biopharmaceutical company committed to advancing treatment paradigms to benefit the lives of patients living with rare diseases, today announced that Nermeen Varawalla, M.D., Ph.D., chief medical officer, will depart the Company in the second quarter of 2023 to pursue other opportunities. The medical affairs team will report to...

Relief Therapeutics Holding SA / Key word(s): AGMEGM Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders 04-Apr-2023 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders Proposes a reverse stock split of its ordinary shares in preparation for planned listing to the Nasdaq Stock Market...

Proposes a reverse stock split of its ordinary shares in preparation for planned listing to the Nasdaq Stock Market GENEVA, SWITZERLAND / ACCESSWIRE / April 4, 2023 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) ("Relief Therapeutics" or the "Company"), a biopharmaceutical company developing and commercializing novel, patent-protected products in select specialty and rare diseases, announced today it has called an extraordinary general meeting ("EGM") of shareholders...

Relief Therapeutics Holding SA / Key word(s): Personnel Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board 03-Apr-2023 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board Dr. Gao has made foundational...

Dr. Gao has made foundational contributions in the discovery and characterization of adeno-associated virus (AAV) serotypes which were instrumental in the resurgence of gene therapy GENEVA, SWITZERLAND / ACCESSWIRE / April 3, 2023 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) ("Relief Therapeutics" or the "Company"), a biopharmaceutical company committed to advancing treatment paradigms to benefit the lives of patients living with rare diseases, today announces the...

Relief Therapeutics Holding SA / Key word(s): Study results Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023 22-March-2023 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by...

Acer Therapeutics reports data from a survey of UCD healthcare providers show taste and odor are the most important attributes when considering treatment options and adherence GENEVA, SWITZERLAND / ACCESSWIRE / March 22, 2023 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )( OTCQB: RLFTF )( OTCQB: RLFTY ) ("Relief Therapeutics"), a biopharmaceutical company committed to advancing treatment paradigms and delivering improvements in efficacy, safety and convenience to benefit the lives of patients...

Relief Therapeutics Holding SA / Key word(s): Study results Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting 17-March-2023 / 22:45 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE ®...

The results of the preclinical study demonstrate improved muscle anabolism and function with a prolonged-release amino acid supplement using Physiomimic Technology™ GENEVA, SWITZERLAND / ACCESSWIRE / March 17, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF) (OTCQB:RLFTY) ("Relief Therapeutics"), a biopharmaceutical company committed to advancing treatment paradigms and delivering improvements in efficacy, safety and convenience to benefit the lives of patients living with rare...